Compare ADMA Biologics Inc (ADMA) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Xpeng Inc - ADR — how do they compare? ADMA Biologics Inc trades at $9.86 (market cap $2.22B), while Xpeng Inc - ADR trades at $11.73 (market cap $11.15B). The key difference: Xpeng Inc - ADR is far larger — about 5× ADMA Biologics Inc's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| ADMA | XPEV | |
|---|---|---|
Market Cap | $2.22B | $11.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $28.07 |
52-Week Low | $7.60 | $11.68 |
Enterprise Value | $2.29B | $13.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
XPeng (XPEV) trades at $11.74, down 2.17% today, with a bearish technical signal but oversold RSI. Revenue surged to $76.72B in 2025, yet net losses persist at -$1.14B. Recent news highlights July 2026 deliveries of 38,027 vehicles, up 4% YoY, and expansion into robotics and autonomous driving.
Outlook: Analyst consensus is bullish with a $17.00 price target, but risks include intense EV competition and ongoing profitability challenges. Upside hinges on new model success and global expansion, while cash flow volatility and high debt remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
